Direktorat Registrasi ObatValid

REXULTI

BPOM Number: DKI2009700917C1
Approved: 27 June 2026
Expiry: 3 January 2030
Form: TABLET SALUT SELAPUT

About This Registration

REXULTI is a BPOM-registered direktorat registrasi obat in Indonesia, registered under number DKI2009700917C1. Its current registration status is Valid, with the licence valid until 3 January 2030. The product is registered to OTSUKA INDONESIA - INDONESIA. BPOM first approved this registration in May 2026. All registration data is sourced directly from the official BPOM public database and updated daily.

Registration data updated by BPOM

This product's registration details were changed on 3 July 2026. This may reflect a status change, renewal, or correction by BPOM.

Registration Details

Application: newaero
Packaging: DUS, 1440 BLISTER @ 10 TABLET SALUT SELAPUT (BULK)
Department: Direktorat Registrasi Obat
Data Last Updated: 3 July 2026

Retail Audit Service

Get detailed market intelligence for this product across Indonesian retail channels

Multiple cities available

Custom questionnaires

Professional shoppers

Detailed reporting

Starting from $50 per city

What's included in the audit service?

Stock availability and positioning verification

Price checking and competitor analysis

Display quality and promotional material assessment

Store condition and customer experience evaluation

Custom questions tailored to your research needs

Professional photographs and detailed reports

Registered Owners

OTSUKA INDONESIA - INDONESIA
KAB. MALANG
NPWP: 12345678910
owner
View profile →

Manufacturing Sites

OTSUKA INDONESIA - INDONESIA
KAB. MALANG
primary
View profile →

Ingredients (1)

BREXPIPRAZOLE

Market Intelligence

Owner Portfolio: OTSUKA INDONESIA - INDONESIA holds 111 BPOM registrations
Manufacturer Scale: OTSUKA INDONESIA - INDONESIA produces 111 registered products
Registration Age: Registered for 1 month
Update Status: Recently updated (20 days ago)

FDA Cross-Reference

via openFDA

Generic Name: BREXPIPRAZOLE
Product Type: HUMAN PRESCRIPTION DRUG
Route of Administration: ORAL

Data sourced from the U.S. FDA drug label database (openFDA). May not exactly match this product variant.

Is this your product?